Legato Capital Management LLC Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Legato Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,040 shares of the specialty pharmaceutical company's stock, valued at approximately $334,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after acquiring an additional 340,854 shares during the last quarter. Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after buying an additional 9,500 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its holdings in shares of ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock worth $13,731,000 after buying an additional 34,416 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after buying an additional 299 shares during the last quarter. Finally, Mizuho Markets Americas LLC purchased a new position in shares of ANI Pharmaceuticals in the third quarter worth $11,670,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

Insider Activity at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the firm's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,381 shares of company stock worth $2,441,556. 12.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price target for the company. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.71.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $0.62 during midday trading on Tuesday, reaching $59.54. The company's stock had a trading volume of 43,634 shares, compared to its average volume of 179,530. The firm has a market capitalization of $1.25 billion, a PE ratio of -108.25 and a beta of 0.74. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a fifty day moving average of $56.98 and a 200 day moving average of $58.23. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.